CORRECTED VERSION*

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
A61K 31/66

A3

(11) International Publication Number: WO 99/04773

(43) International Publication Date: 4 February 1999 (04.02.99)

(21) International Application Number: PCT/US98/14796

(22) International Filing Date: 17 July 1998 (17.07.98)

(30) Priority Data:

60/053,351	22 July 1997 (22.07.97)	US
60/053.535	23 July 1997 (23.07.97)	US
9717590.5	20 August 1997 (20.08.97)	GB
9717850.3	22 August 1997 (22.08.97)	GB

(71) Applicant *(for all designated States except US)*: MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: DAIFOTIS, Anastasia, G. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). SANTORA, Arthur, C., II [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). YATES, A., John [GB/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).

(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).

(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report:
15 April 1999 (15.04.99)

(54) Title: METHOD FOR INHIBITING BONE RESORPTION

(57) Abstract

Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein. The compounds are bisphosphonates selected from the group consisting of alendronate, cimadronate, clodronate, tiludronate, etridronate, ibandronate, risedronate, piridronate, pamidronate, zolendronate, optionally in combination with a histamine H2 antagonist.

*(Referred to in PCT Gazette No. 43/1999, Section II)